Authors and Disclosures
Azita H. Talasaz, PHARMDa,b, Parham Sadeghipour, MDc, Hessam Kakavand, PHARMDa,b, Maryam Aghakouchakzadeh, PHARMDa, Elaheh Kordzadeh-Kermani, PHARMDa, Benjamin W. Van Tassell, PHARMDd,e, Azin Gheymati, PHARMDa, Hamid Ariannejad, MDb, Seyed Hossein Hosseini, PHARMDa, Sepehr Jamalkhanic, Michelle Sholzberg, MDCM, MSCf,g, Manuel Monreal, MD, PHDh, David Jimenez, MD, PHDi, Gregory Piazza, MD, MSj, Sahil A. Parikh, MDk,l, Ajay J. Kirtane, MD, SMk,l, John W. Eikelboom, MBBSm, Jean M. Connors, MDn, Beverley J. Hunt, MDo, Stavros V. Konstantinides, MD, PHDp,q, Mary Cushman, MD, MSCr,s, Jeffrey I. Weitz, MDt,u, Gregg W. Stone, MDk,v, Harlan M. Krumholz, MD, SMw,x,y, Gregory Y.H. Lip, MDz,aa, Samuel Z. Goldhaber, MDj and Behnood Bikdeli, MD, MSj,k,w
aDepartment of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran; bTehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran; cCardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran; dDepartment of Pharmacotherapy and Outcome Science, School of Pharmacy, Virginia Commonwealth University, Richmond, Virginia, USA; ePauley Heart Center, Division of Cardiology, Department of Internal Medicine, School of Pharmacy, Virginia Commonwealth University, Richmond, Virginia, USA; fDepartments of Medicine and Laboratory Medicine & Pathobiology, University of Toronto, Toronto, Ontario, Canada; gDepartment of Medicine, St. Michael's Hospital, Toronto, Ontario, Canada; hDepartment of Internal Medicine, Hospital Universitari Germans Trials i Pujol, Universidad Católica San Antonio de Murcia, Barcelona, Spain; iRespiratory Department, Hospital Ramón y Cajal and Medicine Department, Universidad de Alcalá (Instituto de Ramón y Cajal de Investigación Sanitaria), Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Madrid, Spain; jCardiovascular Medicine Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA; kClinical Trials Center, Cardiovascular Research Foundation, New York, New York, USA; lNewYork-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, USA; mPopulation Health Research Institute, Hamilton Health Sciences, McMaster University, Hamilton, Ontario, Canada; nHematology Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA; oHaemostasis and Thrombosis Centre, St. Thomas' Hospital, London, United Kingdom; pCenter for Thrombosis and Hemostasis, Johannes Gutenberg University of Mainz, Mainz, Germany; qDepartment of Cardiology, Democritus University of Thrace, Komotini, Greece; rDepartment of Medicine, University of Vermont Larner College of Medicine and University of Vermont Medical Center, Burlington, Vermont, USA; sDepartment of Pathology and Laboratory Medicine, University of Vermont Larner College of Medicine and University of Vermont Medical Center, Burlington, Vermont, USA; tDepartment of Medicine, McMaster University, Hamilton, Ontario, Canada; uThrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada; vZena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA; wCenter for Outcomes Research and Evaluation (CORE), Yale School of Medicine, New Haven, Connecticut, USA; xDepartment of Health Policy and Administration, Yale School of Public Health, New Haven, Connecticut, USA; ySection of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA; zLiverpool Centre for Cardiovascular Science, Liverpool Heart and Chest Hospital, University of Liverpool, Liverpool, United Kingdom; and the aaDepartment of Clinical Medicine, Aalborg University, Aalborg, Denmark. Paul F. Bray, MD, served as Guest Associate Editor for this paper. Christie Ballantyne, MD, served as Guest Editor-in-Chief for this paper.
Address for Correspondence
Dr. Behnood Bikdeli, Cardiovascular Medicine Division, Brigham and Women's Hospital, 75 Francis Street, Shapiro 5, Suite 5156, Boston, Massachusetts 02115, USA. E-mail: firstname.lastname@example.org OR Behnood.email@example.com. Twitter: @AzitaTalasaz, @bbikdeli, @BrighamResearch, @harvardmed, @crfheart.
The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors' institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center.
Funding Support and Author Disclosures
Dr. Van Tassell has received research support from Novartis, Swedish Orphan Biovitrum, Olatec Therapeutics, and Serpin Pharma; and is a consultant of R-Pharm and Serpin Pharma. Dr. Monreal has served as an advisor or consultant for Sanofi, Leo Pharma, and Daiichi-Sankyo; and has received a nonrestricted educational grant by Sanofi and Bayer to sponsor the Computerized Registry of Patients with Venous Thromboembolism. Dr. Jimenez has served as an advisor or consultant for Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi-Sankyo, Leo Pharma, Pfizer, ROVI, and Sanofi; has served as a speaker or a member of a speaker bureau for Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi-Sankyo, Leo Pharma, ROVI, and Sanofi; and has received grants for clinical research from Daiichi-Sankyo, Sanofi, and ROVI. Dr. Piazza has received research grant support from Boston Scientific Corporation, Bayer, Bristol Myers Squibb/Pfizer, Portola/Alexion Pharmaceuticals, and Janssen Pharmaceuticals; and has received consulting fees from Amgen, Pfizer, Agile, and Prairie Education and Research Cooperative. Dr. Parikh has received institutional research support from Abbott Vascular, TriReme Medical, SurModics, and Shockwave Medical; is an advisory board member for Abbott Vascular, Boston Scientific, Cardinal Health, Medtronic, Janssen, CSI, and Philips; and receives honoraria from Abiomed and Terumo. Dr. Kirtane has received institutional funding from Medtronic, Boston Scientific, Abbott Vascular, Abiomed, CSI, CathWorks, Siemens, Philips, and ReCor Medical; and has received travel expenses/meals from Medtronic, Boston Scientific, Abbott Vascular, Abiomed, CSI, CathWorks, Siemens, Philips, ReCor Medical, Chiesi, OpSens, Zoll, and Regeneron, all outside the submitted work. Dr. Eikelboom has received honoraria and grant support from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb/Pfizer, Daiichi-Sankyo, GlaxoSmithKline, Janssen, Sanofi, and Eli Lilly, as well as a personal award from the Heart and Stroke Foundation. Dr. Konstantinides has received research grants from Bayer AG, Boehringer Ingelheim, and Actelion-Janssen; has received educational grants from Biocompatibles Group UK, Boston Scientific, and Daiichi-Sankyo; and has received lecture fees from Bayer AG, Bristol Myers Squibb/Pfizer, and Merck Sharp and Dohme. Dr. Weitz serves as a consultant and has received honoraria from Bayer, Janssen, Johnson & Johnson, Bristol Myers Squibb, Pfizer, Boehringer Ingelheim, Novartis, Daiichi-Sankyo, Merck, Servier, Anthos, Ionis, and PhaseBio. Dr. Stone has received speaker or other honoraria from Cook, Terumo, and Orchestra Biomed; has been a consultant to Valfix, TherOx, Vascular Dynamics, Robocath, HeartFlow, Gore, Ablative Solutions, Miracor, Neovasc, V-Wave, Abiomed, Ancora, MAIA Pharmaceuticals, Vectorious, Reva, Matrizyme, and CardioMech; and has equity/options from Ancora, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, MedFocus family of funds, and Valfix. Dr. Krumholz has received personal fees from UnitedHealth, IBM Watson Health, Element Science, Aetna, Facebook, Siegfried & Jensen Law Firm, Arnold & Porter Law Firm, Ben C. Martin Law Firm, and the National Center for Cardiovascular Diseases (Beijing, China); has ownership in Hugo Health and Refactor Health; and has contracts from the U.S. Centers for Medicare & Medicaid Services; and has received grants from Medtronic, the U.S. Food and Drug Administration, Johnson & Johnson, and the Shenzhen Center for Health Information, outside the submitted work. Dr. Lip is a consultant for Bayer/Janssen, Bristol Myers Squibb/Pfizer, Medtronic, Boehringer Ingelheim, Novartis, Verseon, and Daiichi-Sankyo; and is a speaker for Bayer, Bristol Myers Squibb/Pfizer, Medtronic, Boehringer Ingelheim, and Daiichi-Sankyo (no fees are directly received personally). Dr. Goldhaber has received research support from Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Boston Scientific, Daiichi-Sankyo, Janssen, the National Heart, Lung, and Blood Institute, and the Thrombosis Research Institute; and has received consulting fees from Bayer, Agile, Boston Scientific, and Boehringer Ingelheim. Dr. Bikdeli is a consulting expert, on behalf of the plaintiff, for litigation related to 2 specific brand models of inferior vena cava filters. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.